Table 2. Outcome measures of TPO-RA group versus control group.
| Study | N | OR (Y/N) |
DR (Y/N) |
Rescue medication (Y/N) |
Any bleeding (Y/N) |
Serious bleeding (Y/N) |
Clinically significant bleeding. (Y/N) |
HQoL | Parental burden | All AEs (Y/N) |
Serious AEs (Y/N) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TPO-RA | Control | TPO-RA | Control | TPO-RA | Control | TPO-RA | Control | TPO-RA | Control | TPO-RA | Control | TPO-RA | Control | TPO-RA | Control | TPO-RA | Control | TPO-RA | Control | ||
| Tarantino (2016) | 62 | 30/12 | 4/16 | 22/20 | 2/18 | 6/36 | 2/18 | 35/7 | 14/5 | 5/37 | 1/18 | - | - | - | - | - | 10/32 | 1/18 | |||
| Mathias (2016) | 62 | - | - | - | - | - | - | - | - | 80.2 ± 14.8 | 78 ± 18.9 | 53.7 ± 25.4 | 49.4 ± 18.2 | - | - | ||||||
| Klaassen (2012) | 22 | - | - | - | - | - | - | - | - | 81.2 ± 13.3 | 75.5 ± 21.1 | 61.8 ± 21 | 29.8 ± 1.9 | - | - | ||||||
| Elalfy (2011) | 18 | 10/2 | 0/6 | - | - | 1/11 | 2/4 | - | - | 0/12 | 2/4 | - | - | - | - | 6/6 | 3/3 | 0/12 | 0/6 | ||
| Bussel (2011) | 22 | 15/2 | 0/5 | 12/5 | 1/4 | 2/15 | 2/3 | 12/5 | 2/3 | 0/17 | 0/5 | 1/16 | 0/5 | - | - | - | - | 16/1 | 5/0 | 1/16 | 1/4 |
| Grainger (2015) | 92 | 47/16 | 6/23 | 25/38 | 1/28 | 12/41 | 7/22 | 45/18 | 20/9 | - | - | 3/60 | 2/27 | 51/12 | 21/8 | 5/58 | 4/25 | ||||
| Bussel (2015) | 67 | 28/17 | 7/15 | 16/29 | 0/22 | 6/39 | 11/11 | 14/31 | 18/4 | 0/45 | 2/20 | 4/41 | 7/15 | 36/9 | 20/2 | 4/41 | 2/20 | ||||
N : number of the patients; OR: overall platelet response; Y/N : yes/no; DR: durable response; HqoL: health-related quality of life; AEs: adverse events.